Compared to the other treatment categories, patients receiving local and systemic treatment more often had primary rectal tumours (19% compared to <7% in other categories), BRAF wildtype tumours (65% compared to <49% in other categories) and were younger (≤55 years in 42% versus <23% in other categories), as shown in Supplementary Table S5. This evidence concerns the gene BRAF and rectal neoplasm.